منبع پایان نامه درمورد Haemophilus، influenzae، Infect، membrane

بخش‌های متغیر دارای بخش‌های حفاظت شده می‌باشد که می‌توان از آنها به عنوان کاندیدای واکسن استفاده کرد. با توجه به اینکه واکسن فعلی با استفاده از PRP ساخته می‏شود ،بعلت جنس پلی ساکاریدی این آنتی ژن، در بدن افراد و بخصوص کودکان زیر 2 سال، ایمنی فعال ایجاد نمی‌کند. همین طورPRP آنتی ژن مختص سویه‌های کپسول دار به حساب می‌آید. اما آنتی ژن‌های پروتئینی همان طور که بیان نمودیم قادر به ایجاد ایمنی فعال وابسته به لنفوسیت T در تمام سویه‌های باکتری هستند.

پیشنهادات:
1-در سویه‌های بیشتری از هموفیلوس آنفلوانزا پلی مورفیسم ژن ompP2 بررسی شود.
2-بیان ژن پروتئین P2 توسط تکنیک Real time PCR بررسی شود.
3-مطالعات بی زیانی و توکسیسیتی پروتئین P2 روی مدل‌های حیوانی انجام شود و سپس وارد فازهای بالینی گردد.
4-در مدلهای حیوانی، ارزیابی ایمونولوژیکی پروتئین P2 انجام شود.
5-بر روی انواع سروتایپ این باکتری، آنالیز مولکولی این ژن انجام شود.
6-تکرار این مطالعه با تعداد بیشتری سویه بالینی که از نقاط مختلف کشور ایزوله می‌شوند صورت بگیرد.
7-بهره گیری از تکنیک‌هایی همچون تکنیک
LAMP (Loop-mediated isothermal amplification of DNA) برای نواحی بسیار حفاظت شده این ژن، می‌تواند کمک موثری در اهداف تشخیصی فراهم کند.

منابع

فهرست منابع

References:
1- Ahren,l. L. ,H. Janson ,et al. (2001)Protein D expression promotes the adherence and internalization of non-typeable Haemophilus influenza into human monocytic cells. Microbial Pathogenesis 31(3):151-158.
2- Alrawi, A. M., K. C. Chern, el al. (2002). Biotypes and serotypes of Haemophilus influenzae molecular isolates.British Journal of ophthalmology 86(3):276-277.
3- Berenson CS, Murphy TF, Wrona CT, Sethi S. Outer membrane protein p6 ofnontypeable Haemophilus influenzae is a potent andselective inducer of human macrophageproinflammatory cytokines. Infect Immun. 2005;73: 2728-2735.
4- Breukels MA, Spanjaard L, Sanders LA, Rijkers GT. Immunological characterization of conjugated Haemophilus influenzae type b vaccine failure in infants.Clin Infect Dis. 2001; 32:1700.
5- Cotter D, Manson K, Howell AP, Fink DL, Green BA. Immunization with Haemophilus influenzae Hapadhesin protects against nasopharyngeal colonizationin experimental mice. J Infect Dis. 2002; 186:1115-1121.
6- Cotter SE, Yeo HJ, JuehneT, St Geme I. Architecture and adhesive activity of the Haemophilus influenza Hsfadhesin. وJBacteriol. 2005; 187:4656-4664.
7- Doran L. Fink 1, 2,3Amy Z. Buscher1, 2, 3, Bruce Green4, phillip Fernsten4,JosephW. St. Gemel1, 2, 3, Article the first public shed online (March2003):4MAR 2003 DOI:10. 1046/j. 1462-5822.2003. 00266. x:The Haemophilus influenza Hap autotransporter mediates microcolony formation and adherence to epithelial cells and extracellular matrix via binding in the C-terminal end of the passenger domain. Cellular Microbiology Volume 5,Issue 3,pages175-186.
8- Duim B,1993. Genetic analysis of the diversity in outer membrane protein P2 of non-encapsulated Haemophilus influenza.Microbial pathogenesis,1993;14:451-462. Available from: http://books.google.com/books?id=ZXFcBAAAQBAJ&pg=PA100&lpg=PA100&dq=genetic+analysis+of+the+diversity+in+outer+membrane+protein[1392/4]
9- Dworkin,M. S. ,park,L. ,Borchardt,S. M. ,2007. The changing epidemiology of invasive Haemophilus disease ,especially in persons65 years old. clin. Infect. Dis. 44,810-816.5,Issue 3,pages175-186.
10- Dworkin,M. S. ,park,L. ,Borchardt,S. M. ,2007. The changing epidemiology of invasive Haemophilus disease ,especially in persons65 years old. clin. Infect. Dis. 44,810-816.
11- Esmaily.F,A. M. ,Tavangar. AR,Hadi. A(2011). Comparison of bacterial biomass and PRP production between different isolates of Haemophilus influenza type b (Hib) under different culture conditions.Razi vaccine &Serum Research Institute66(1):7.
12- Forbes KJ and el,1992,Variation in length and sequence of porin (ompP2) alleles of non-capsulate Haemophilus influenzae. 1992,Mol Microbiol. 2107-12. Available from: http://www.ncbi. nlm. nih. gov/pubmed/1328812[1392/5]
13- Forsgren A, Riesbeck K, Janson H. Protein D of Haemophilus influenzae: a protectivenontypeable Haemophilus influenzae antigen and acarrier for pneumococcal conjugate vaccines. . Clin Infect Dis. 2008;46: 726-731.
14- FoxwellAR,KydJM,CrippsAW. Nontypeable Haemophilusinfluenzae: pathogenesis and prevention. Microbiol Mol Biol Rev. 1998;62:294–308.
15- Goldblatt D, VazAR, Miller E. Antibody avidity as a surrogatemarker of successful priming by Haemophilus influenzatype b conjugate vaccines following infant immunization.J Infect Dis. 1998;177:1112.
16- Haase EM, Morse GD, Murphy TF.Mapping of Bactericidal Epitopes on the P2 Porin Protein of Nontypeable Haemophilus influenzae.Infect Immun. 1994;62(9):3712-22. . Available from: http://www.ncbi. nlm. nih. gov/pmc/articles/PMC303022[1392/4].
17- Hiltke, T. J. , S. Sethi, and T. F. Murphy, Sequence stability of the gene encoding outer membrane protein P2 of nontypeable Haemophilus influenzae in the human respiratory tract. J Infect Dis, 2002. 185(5): p. 627-31
18- Hiltke Tj and el,2003, Horizontal transfer of the gene encoding outer membrane protein P2 of nontypeable Haemophilus influenzae, in a patient with chronic obstructive pulmonary disease. 2003,PUBMED,1;188(1):114-7. http://www.ncbi. nlm. nih. gov/pubmed/12825179,[1392/4]
19- Hiltke Tj el,2002. Sequence stability of the gene encoding outer membrane protein P2 of nontypeable Haemophilus influenzae in the human respiratory tract.J Infect Dis. 2002 Mar 1;185(5):627-3,Available from: http://www. ncbi. nlm. nih. gov/pubmed/11865419,[1393/3]
20- Inoshima,Y. ,A. Morooka,et al. (2000)Simple preparation of parapoxvius genome DNA for endonuclease analysis. Microbiology and Immunology 44(1):69-72.
21- Ishida Y،Abe Y،Yanaia M،Kobayashi H،Harabuch Y. Identification of human T-cell epitopes and highlyimmunogenic analog peptides on the non-typeableHaemophilus-influenzae P6 outer membrane protein.Clin Immunol. 2006;121:90-99.
22- Janson,H. ,M. Ruan,et al. (1993). Limited diversity of the Protein –D gene (HPI)amoung encapsulated and noncapsulated Haemophilus-Influenzae strains. Infection and Immunity 61(11):4546-4552.
23- Kennedy S. ,Oswald N. ,PCR Troubleshooting and optimization :The Essential Guide ,1stedn. 2011. Available from: http://www.amazon. com/PCR-Troubleshooting –Optimization-Essential-Guide/dp/1904455727.
24- Kubiet, M. and Ramphal, R. (1995) Adhesion of nontypeable Haemophilusinfluenzae from blood and sputum to human tracheobronchial mucins andlactoferrin. Infect. Immun. 63,899–902.
25- Kyd JM, Cripps AM, Novotny LA, Bakaletz LO. Efficacy of the 26-Kilodalton Outer Membrane Protein and Two P5Fimbrin-Derived Immunogens To Induce Clearance of NontypeableHaemophilus influenzae from the Rat Middle Ear and Lungs asWell as from the Chinchilla Middle Ear and Nasopharynx. Infect Immun. 2003;71(8):4691-4699.
26- Ladhani,S. ,Slack,M. P. ,White,j. ,Ramsay,Fall in Haemophilus influenezae serotype b(Hib) disease following implementation of a boostercampain. Arch. Dis. child.93,665669.
27- Larson,T. J. ,Ehrmann,et al. (1983). Periplasmic Glycerophosphodiester phosphodiesterase of
Escherichia –Coli,A New Enzyme of the Glp Regulon. journal of Biological Chemistry 258(9):5428-5432.
28- Lindberg A. Glycoprotein conjugate vaccines. Vaccine.1999;17:s28-s36. 44-Ada G, Isaacs D. Carbohydrate- protein vaccines.Clin Microbiol Infect. 2003; 9:79-85.
29- Orkin ,S. (1990). Molecular cloning a laboratorymanual,2nedition,sambrook,j ,Fritsch, EF,Maniatis,T. Nature 343(6259)604-605.
30- Mandell GL, Bennett JE, Dollin R. Principles and practice of infectious disease.7th edition, Churchill Livingstone, Elsevier;2010,1, P. 1079-1171.
31- Mandell GL, Bennett JE, Dollin R. Principles and practice of infectious disease.7th edition, Churchill Livingstone, Elsevier;2010,vol. 2, P. 2911-2921.
32- Manson ,RS,et al,Purfication and comparison of outer membrane protein P2 from Haemophilus influenza Type b isolates. Clinical Investigation.1983;72(2):677–684. doi:10. 1172/JCI111017. Available from: http://www.jci.org/articles/view/111017[1393/3]
33- Martin, D. , et al. , Mapping of B-cell epitopes on the outer membrane P2 porin protein of Haemophilus influenzae by using recombinant proteins and synthetic peptides.Infect Immun, 1991. 59(4): p. 1457-64
34- Metcalf BJ.Production of thelapidated formof the Peptidoglycan-associatedlipoproteinsofgram-negativebacteria. Available from: http://www. faqs. org/patents/app/20090060952).
35- Meyers,J. A. ,D. Sanchez,et al. (1976). Simple agarose-gel electrophoretic method for identification and characterization of plasmid deoxyribonucleic-acid.Journal of Bacteriology 127(3):1529-1537.
36- Moreno, E. 1999.Purification and characterization of smooth and rough lipopolysaccharides from Brucella abortus. Infect. Immun. 43: 779
37- Murley YM, Edlind TD, Plett PA, LiPuma JJ.Cloning of thehaemocin locus of Haemophilus influenzaetype b and assessment of the role of haemocinin virulence.Microbiology.1998;144: 2531-2533.
38- Murphy TF, Bartos LA, Campagnari AA, Nelson MB, Apicella MA.Antigenic -Characterization of the P6 Protein of Nontypable Haemophilus influenzae. Infect Immun. 1986;54(3):774-779.
39- Murphy TF, Pastor P, Medley F, Osterholm MT, GranoffDM.Decreased Haemophilus colonization in children vaccinatedwith Haemophilus influenzae type b conjugate vaccine.J Pediatr.1993;122:517.
40- Murphy TF.Respiratory infections caused by non-typeable Haemophilusinfluenzae. Curr Opin Infect Dis 2003;16:129–34.
41- Musser, J. M. , Barenkamp, S. J. , Granoff, D. M. , and Selander, R. K. (1986)Genetic relationships of serologically nontypeable and serotype b strains ofHaemophilus influenzae. Infect. Immun. 52,183–191.
42- Nakamura M, Asaka T, Kirita A, Miyazaki H, Senda Y, Fujita SI, Fukushima R. Occurrence of the Fimbria GenehifA in Clinical Isolates of nonencapsulated-Haemophilus influenzae. Microbiol Immunol. 2006; 50:327-329.
43- Niazi A. Rahman,Comparison of Virulence Determinants of DifferentStrains of Haemophilusinfluenzae. School of Biomedical Science,Curtin University of Technology, Perth WA,Australia,2009.
44- Peltola H. Worldwide Haemophilus influenzae Type b Disease at the Beginningof the 21st Century: Global Analysis of the Disease Burden25 Years after the Use of the Polysaccharide Vaccineand a Decade after the Advent of Conjugates. Clin Microbiol Rev. 2000;13(2):302-317.
45- Prasadarao,N. V. ,E. Lysenko,et al. (1999). Opacity associated protein a contributes to the binding of Haemophilus influenza to chang epithelial cells. Infection and Immunity 67(8):41534160.
46- Pickering Jerry W, Martins Thomas B,Schroder M. Carl and Hill Harry R. ,2002,Comparison of a multiplex flow cytometric assay with enzyme-linked immunosorbent assay for quantitation of antibodies to tetanus,Diphtheria and Haemophilus influenzatype b. Clin vaccine. Immunol,9(4): 879-876.
47- Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typableHaemophilus influenzae: a randomised double-blindefficacy study. Lancet.2006; 367:740-748.
48- Reddy, M. S. , Bernstein, J. M. , Murphy, T. F. , Faden, H. (1996) Bindingbetween outer membrane proteins of nontypeable Haemophilus influenzae andhuman nasopharyngeal mucin. Infect. Immun. 64.1447–1449.
49- Read,T. D. ,S. W. Satola,et al. (1998). Copy number of pilus gene clusters in Haemophilus Influenzae and variation in the hifE pilin gene. Infection and Immunity 66(4):1622-1631.
50- Roche R. and Maxon.E,1995,Phenotype variation in Haemophilus influenza:The Interrelationship of colony opacity,conjugate and rotavirus vaccines in national immunization schedules,Health Econ. 9:19-35Bishai,Howard,Winkelstein,and Smith,1994,Characterization and Virulence Analysis of Catalas Mutants of Haemophilus influenza,Infection and Immunity,P. 48554860.
51- San Martin,B. ,L. Lapierre,et al. (2008).

پاسخی بگذارید

نشانی ایمیل شما منتشر نخواهد شد. بخش‌های موردنیاز علامت‌گذاری شده‌اند *